IDO1 and ovarian cancer: In this study, using preclinical models and clinical specimens, we determine that targeting TRP metabolism via a dual TDO2/IDO1 inhibitor reduces protumor intrinsic cell phenotypes as well as immunosuppressive markers in macrophages, which could be clinically impactful in ovarian cancer.